Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | NPC1 | O15118 | 7/20 | 0.66 |
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12181187 | 0.90 | KDM4E (0.81) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL6127192 | 0.84 | KDM4E (0.89) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL4578939 | 0.84 | KDM4E (0.77) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL4578943 | 0.84 | KDM4E (0.77) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL3077089 | 0.82 | KDM4E (0.74) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL10358749 | 0.82 | KDM4E (0.74) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL8657462 | 0.82 | KDM4E (0.74) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL8443436 | 0.81 | KDM4E (0.84) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL18906066 | 0.81 | KDM4E (0.83) | KDM4ENPC1RAB9ASMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL31169755 | 0.81 | KDM4E (0.72) | KDM4ENPC1RAB9ASMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019174279-A1 | 1,2-BENZISOSELENAZOL-3(2H)-ONE AND 1,2-BENZISOTHIAZOL-3(2H)-ONE DERIVATIVES AS BETA-LACTAM ANTIBIOTIC ADJUVANTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2019-09-19 | — | — | WO | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20170152443-A1 | LIQUID CRYSTAL ALIGNMENT AGENT, LIQUID CRYSTAL ALIGNMENT FILM, AND LIQUID CRYSTAL DISPLAY ELEMENT | CHI MEI CORPORATION (TW) | 2017-06-01 | — | — | US | disclosed |
| US-8697691-B2 | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-04-15 | — | — | US | disclosed |
| US-8697691-B2 | Alkyl 3-((2-amidoethyl)amino)-8-azabicyclo[3.2.1]octane-8-carboxylate analogs as selective M1 agonists and methods of making and using same | VANDERBILT UNIVERSITY (US) | 2014-04-15 | — | — | US | disclosed |
| US-8455477-B2 | Therapeutic compounds | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110207711-A1 | Therapeutic Compounds | MSD K.K. (JP) | 2011-08-25 | — | — | US | disclosed |
| WO-2011087812-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110172227-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| US-20110172227-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| WO-2010017047-A1 | THERAPEUTIC COMPOUNDS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-4568691-A | Anti-inflammatory esters of 4-(1-hydroxy-2-[(acylamino)-alkylamino]-ethyl)-phenol derivatives, compositions, and method of use therefor | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1986-02-04 | — | — | US | disclosed |
| EP-0082665-B1 | PHENOL ESTERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-07-17 | — | — | EP | disclosed |
| US-4520027-A | Anti-inflammatory esters of 4-(1-hydroxy-2-[(acylamino)alkylamino]ethyl) phenols | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-05-28 | — | — | US | disclosed |
| EP-0082665-A1 | Phenol esters | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1983-06-29 | — | — | EP | disclosed |
| US-4387099-A | Alkanolamine derivatives | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1983-06-07 | — | — | US | disclosed |
| US-4327113-A | DRUGS FOR TREATMENT OF HEART DISEASES, ADRENERGIC BLOCKING AGENTS, ETC | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1982-04-27 | — | — | US | disclosed |
| US-4260632-A | ADRENERGIC BLOCKING AGENTS, CARDIOVASCULAR DISORDERS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-04-07 | — | — | US | disclosed |
| US-4221807-A | ADRENERGIC BLOCKING AGENTS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-09-09 | — | — | US | disclosed |
| US-4141987-A | HYPOTENSIVE, ADRENERGIC BLOCKING AGENT | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207711-A1 | Therapeutic Compounds | WEE2, MARK3, WEE1 | KDM4E 1778/4885NPC1 1378/4885RAB9A 2116/4885 |
| US-20110172227-A1 | ALKYL 3-((2-AMIDOETHYL)AMINO)-8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXYLATE ANALOGS AS SELECTIVE M1 AGONISTS AND METHODS OF MAKING AND USING SAME | CHRM1, CHRM2, CHRM5 | KDM4E 1558/4885NPC1 861/4885RAB9A 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.